Quarterly ResultMay 15, 2026, 08:38 AM
Cocrystal Pharma Cash Drops to $4.76M; Going Concern Warning
AI Summary
Cocrystal Pharma reported a net loss of $2.30 million for the three months ended March 31, 2026, similar to the prior year. The company's cash and restricted cash significantly decreased to $4.76 million from $7.10 million at December 31, 2025, with $2.34 million used in operating activities. Management explicitly stated that current resources are insufficient to fund operations beyond the next 12 months, raising substantial doubt about its ability to continue as a going concern.
Key Highlights
- Cash and restricted cash decreased to $4.76 million as of March 31, 2026, from $7.10 million at December 31, 2025.
- Net loss for Q1 2026 was $2.30 million, comparable to $2.30 million in Q1 2025.
- Net cash used in operating activities was $2.34 million in Q1 2026, down from $2.94 million in Q1 2025.
- Total assets decreased to $7.43 million at March 31, 2026, from $9.71 million at December 31, 2025.
- Total stockholders' equity fell to $4.12 million at March 31, 2026, from $6.33 million at December 31, 2025.
- Research and development expenses were $1.37 million in Q1 2026, slightly up from $1.36 million in Q1 2025.
- General and administrative expenses increased to $1.21 million in Q1 2026 from $0.98 million in Q1 2025.
- The company recognized $0.23 million in grant income in Q1 2026, compared to none in Q1 2025.
Price Impact
More from COCP